Risk factors

Xilio Therapeutics (XLO) risk factors

Item 1A of every Xilio Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open XLO in Gloomberb →
  • FY2025 10-K risk factors

    175 risks, 103 new, 14 dropped, 28 reworded since the prior year. Xilio is developing masked immuno-oncology candidates, funded into 2027 with $137.5M cash plus recent equity and AbbVie milestone proceeds.

    Filed Mar 23, 2026
  • FY2024 10-K risk factors

    86 risks. Xilio is entirely dependent on its clinical-stage pipeline candidates, primarily vilastobart and XTX301, with no commercial products or revenue.

    Filed Mar 11, 2025